News & Events about Prothena Corporation Plc.
Business Wire
2 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (A) product...
Ticker Report
3 months ago
Prothena Co. plc (NASDAQ:PRTA Get Rating) Stock analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Prothena in a research note issued to investors on Friday, February 24th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company ...
Business Wire
5 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the...
Business Wire
5 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with...
Business Wire
7 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at the...